Hypocalcemia News and Research

RSS
AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

State court jury rules in favor of Merck in FOSAMAX trial

State court jury rules in favor of Merck in FOSAMAX trial

Enobia Pharma completes ENB-0040 Phase II study in juveniles with hypophosphatasia

Enobia Pharma completes ENB-0040 Phase II study in juveniles with hypophosphatasia

EDMA to endorse the campaign on Hypoparathyroidism

EDMA to endorse the campaign on Hypoparathyroidism

Merck wins third FOSAMAX bellwether trial

Merck wins third FOSAMAX bellwether trial

Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

Denosumab superior to Zometa in preventing SREs in breast cancer patients with bone metastases: Study

Denosumab superior to Zometa in preventing SREs in breast cancer patients with bone metastases: Study

Amgen wins Scrip Best New Drug award for Prolia

Amgen wins Scrip Best New Drug award for Prolia

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

New data on Merck’s odanacatib for osteoporosis in postmenopausal women presented at 32nd ASBMR

New data on Merck’s odanacatib for osteoporosis in postmenopausal women presented at 32nd ASBMR

Amgen to present oncology portfolio results at ESMO Congress

Amgen to present oncology portfolio results at ESMO Congress

Merck to appeal against jury verdict in retrial of federal FOSAMAX case

Merck to appeal against jury verdict in retrial of federal FOSAMAX case

Enobia announces positive results from ENB-0040 Phase II juvenile clinical trial for hypophosphatasia

Enobia announces positive results from ENB-0040 Phase II juvenile clinical trial for hypophosphatasia

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

Merck challenges New York jury decision in federal FOSAMAX retrial

Merck challenges New York jury decision in federal FOSAMAX retrial

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Phase 3 trial demonstrates superiority of Amgen's denosumab over Zometa in preventing SREs

Phase 3 trial demonstrates superiority of Amgen's denosumab over Zometa in preventing SREs